Intrexon | XON - Selling And Administration Expenses


Intrexon reported $10.31M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
Amgen USD 1.72B 134M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 351.73M 23.64M Jun/2026
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
MannKind USD 58.3M 4.22M Jun/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Thermo Fisher Scientific USD 1.91B 111M Jun/2026
Veracyte USD 55.71M 4.87M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026